Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Market Gems:Stocks w/Strong Earnings and High Tech. Rank -- Ignore unavailable to you. Want to Upgrade?

To: croonerjim who wrote (95978)	5/3/2000 9:25:00 PM
From: Jenna	Read Replies (2) \| Respond to of 120523

AMRI.. Is this stock a secret? Up grandly today on almost no volume. Earnings out Tuesday looking for $0.24 versus $0.21. This one moves down when the market is up and up when he market is down. Trades at a 17% Discount PE Multiple of 45.4 X, vs. the 54.8 X average multiple at which the Biomedics SubIndustry is priced. Consensus Future 5-yr Growth Rate: 23.67%, 18% earnings surprise last quarter. Albany Molecular Research, Inc. Reports 94% Increase in Quarterly Earnings on Record Revenue ALBANY, N.Y., Feb 8, 2000 (BUSINESS WIRE) -- Albany Molecular Research, Inc. (NASDAQ: AMRI) today announced operating results for the quarter and year ended December 31, 1999. Net contract revenue for the fourth quarter of 1999 increased by 74% to $6.7 million over net contract revenue of $3.8 million in the comparable period of 1998. Recurring royalties for the fourth quarter of 1999 were $5.6 million, a 71% increase over recurring royalties of $3.2 million in the fourth quarter of 1998. Royalty revenue is earned from worldwide sales of the non-sedating antihistamine Allegra(tm), resulting from a 1995 licensing agreement the Company entered into with Aventis S.A., the manufacturer of Allegra(tm), and successor to Hoechst Marion Roussel. ``Our biggest challenge is to manage the rapid growth we continue to experience,'' claims Thomas D'Ambra, CEO of Albany Molecular Research (Nasdaq: AMRI - news). ``It is important that our expanding organization continues to meet the high standards that our customers have come to expect from AMRI.